ArticleFrontiers in veterinary science2022
Pharmacokinetic/Pharmacodynamic Relationships of Tulathromycin Against
Article in Frontiers in veterinary science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Analgesic and antioxidant potential of tulathromycin: evidence from molecular docking, in vitro assay, and in vivo model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Dose Optimization of Tilmicosin againstJournal of agricultural and food chemistry · 2026Article
- Serotyping and antimicrobial resistance of Actinobacillus pleuropneumoniae isolates from fattening pigs in Poland from 2019 to 2024.BMC veterinary research · 2025Article
- Eco-conscious potentiometric sensing: a multiwalled carbon nanotube-based platform for tulathromycin monitoring in livestock products.BMC chemistry · 2024Article
- Evaluation the kill rate and mutant selection window of danofloxacin against Actinobacillus pleuropneumoniae in a peristaltic pump model.BMC veterinary research · 2024Article
- Susceptibility evaluation and PK/PD integration of tulathromycin againstFrontiers in veterinary science · 2024Article
- Evaluation of Biological Equivalence for Generic Tulathromycin Injections in Cattle.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tulathromycin is a semi-synthetic macrolide antibiotic that is highly effective in treating respiratory tract bacterial infections. We evaluated the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.